TARO PHARMACEUTICAL INDUS (TARO) Stock Balance Sheet
NYSE:TARO - IL0010827181 - Common Stock
42.97 USD
0 (0%)
42.97 USD
0 (0%)
| 2024 (2024-3-31) | 2023 (2023-3-31) | 2022 (2022-3-31) | 2021 (2021-3-31) | 2020 (2020-3-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | 58.95M | 120.00M | 47.60M | N/A | N/A | |||
| Cash Equivalents | 362.91M | 154.50M | 251.10M | 605.20M | 513.40M | |||
| Marketable Securities | 457.50M | 575.80M | 522.00M | 418.50M | 595.40M | |||
| Receivables | 219.24M | 247.70M | 293.50M | 254.00M | 264.20M | |||
| Inventories | 204.82M | 226.70M | 210.40M | 180.30M | 153.10M | |||
| Other Current Assets | N/A | 11.70M | 13.20M | 12.90M | 6.60M | |||
| Total Current Assets | 1.30B | 1.34B | 1.34B | 1.47B | 1.53B | |||
| Non-Current Assets | ||||||||
| PPE Net | 217.59M | 194.00M | 205.10M | 208.20M | 212.20M | |||
| Investments And Advances | 457.99M | 404.90M | 435.20M | 557.20M | 459.60M | |||
| Goodwill | 17.23M | 17.20M | 11.80M | 7.20M | 7.20M | |||
| Intangibles | N/A | 63.60M | 47.30M | 6.80M | 8.40M | |||
| Other Non-Current Assets | 165.85M | 119.40M | 139.00M | 156.60M | 121.30M | |||
| Total Non-Current Assets | 858.67M | 799.10M | 838.50M | 936.10M | 808.70M | |||
| TOTAL ASSETS | 2.16B | 2.14B | 2.18B | 2.41B | 2.34B | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | N/A | N/A | |||
| Accrued Expenses | N/A | 49.00M | 51.20M | 42.40M | 37.30M | |||
| Accounts Payable | 44.66M | 90.90M | 87.60M | 78.00M | 66.00M | |||
| Other Current Liabilities | 316.44M | 245.70M | 293.30M | 555.90M | 119.40M | |||
| Total Current Liabilities | 361.11M | 385.50M | 432.10M | 676.30M | 222.70M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Deferred Taxes/Income | 7.96M | 19.11M | 32.80M | 1.90M | 3.40M | |||
| Other Non-Current Liabilities | N/A | 19.10M | 32.80M | 33.20M | 5.40M | |||
| Total Non-Current Liabilities | 7.96M | 19.20M | 32.80M | 26.90M | 14.70M | |||
| TOTAL LIABILITIES | 369.06M | 404.70M | 464.90M | 703.20M | 237.40M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | N/A | 2.41B | 2.39B | 2.34B | 2.73B | |||
| Additional Paid In Capital | N/A | 262.40M | 262.40M | 262.40M | 262.40M | |||
| Minority Interest | N/A | N/A | 0.00 | -8.20M | 5.90M | |||
| Common Shares | N/A | 700.00K | 700.00K | 700.00K | 700.00K | |||
| Treasury Stock | N/A | -771.40M | -771.40M | -746.50M | -721.50M | |||
| Other Shareholders' Equity | 1.79B | -175.00M | -169.00M | -151.60M | -163.00M | |||
| Shares Outstanding | 37.59M | 37.60M | 37.60M | 37.90M | 38.30M | |||
| Tangible Book Value per Share | 47.24 | 43.89 | 43.94 | 44.58 | 54.52 | |||
| Total Shareholders' Equity | 1.79B | 1.73B | 1.71B | 1.70B | 2.10B | |||
| TOTAL LIABILITIES AND EQUITY | 2.16B | 2.14B | 2.18B | 2.41B | 2.34B | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | |||
| Current Ratio | 3.61 | 3.47 | 3.10 | 2.17 | 6.88 | |||
| Return On Assets (ROA) | 2.49% | 1.19% | 2.68% | -16.07% | 10.43% | |||
| Return On Equity (ROE) | 3.00% | 1.47% | 3.41% | -22.70% | 11.61% | |||
| Return On Invested Capital (ROIC) | 0.79% | 0.67% | 4.72% | 5.52% | 7.66% | |||
| Return On Invested Capital Ex Cash (ROICexc) | 1.44% | 1.14% | 8.47% | 13.51% | 16.07% | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | 1.47% | 1.24% | 9.02% | 13.78% | 16.32% | |||
All data in USD , ROIC based on taxRate of 0.34